Drug profile

The FDA adverse-event record for Leptosporosis Vaccine

16 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Leptosporosis Vaccine. See the species affected, top reactions, and outcomes below.

16
adverse-event reports
31.3%
death-coded share
Dog
most-reported species
4
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
5
Deaths Reported
31.3%
Death Rate

Active Ingredients

Leptosporosis Vaccine

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 16

Most Affected Breeds

Retriever - Labrador 2
Siberian Husky 1
Spaniel (unspecified) 1
Chihuahua 1
Dog (unknown) 1
Terrier (unspecified) 1
Poodle - Standard 1
Dachshund (unspecified) 1
Terrier - Bull - American Pit 1
Crossbred Canine/dog 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 4
Vomiting 3
Death 3
Thrombocytopenia 2
Other abnormal test result NOS 2
Death by euthanasia 2
Cough 2
Elevated serum alkaline phosphatase (ALP) 2
Proprioception deficit 2
Limb weakness 2
Urinary incontinence 2
Medication error NOS 2

Outcome Breakdown

Ongoing
7 (43.8%)
Recovered/Normal
3 (18.8%)
Died
3 (18.8%)
Euthanized
2 (12.5%)
Outcome Unknown
1 (6.3%)

Leptosporosis Vaccine Adverse Event Insights

16 reports name Leptosporosis Vaccine; 5 recorded a death outcome (31.3% of reported events, not a population-level mortality rate). Active ingredient: Leptosporosis Vaccine. Administration routes: Unknown, Subcutaneous.

By species: Dog (16 reports). By breed: Retriever - Labrador (2), Siberian Husky (1), Spaniel (unspecified) (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (4), Vomiting (3), Death (3), Thrombocytopenia (2). Outcome, 16 coded reports: Ongoing leads at 43.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.